Abstract
Introduction Standard FCR therapy in untreated CLL patients (F-25 mg/m2 d1–3 q 4wk; C-250 mg/m2 d 1–3 q 4wk; R-500 mg/m2 d1 q 4wk for 6 cycles) was reported to have complete remissions (CR) of 70% and overall responses (OR) of 95% (
J Clin Oncol
2005
;23
:4079
Author notes
Disclosure:Research Funding: This study is supported by Genentech, Inc. Membership Information: Dr. Ken Foon is on Genentech’s Speaker’s Bureau.
2007, The American Society of Hematology
2007
This feature is available to Subscribers Only
Sign In or Create an Account Close Modal